Molecular Templates, Inc.

NasdaqCM:MTEM Rapport sur les actions

Capitalisation boursière : US$10.3m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Molecular Templates Gestion

Gestion contrôle des critères 3/4

Le PDG Molecular Templates' est Eric Poma, nommé en Jan2009, a un mandat de 15.58 ans. La rémunération annuelle totale est $ 857.77K, composée du salaire de 72.4% et des bonus 27.6%, y compris les actions et options de la société. détient directement 0.28% des actions de la société, d'une valeur de $ 28.80K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 1 ans et 7 ans.

Informations clés

Eric Poma

Directeur général

US$857.8k

Rémunération totale

Pourcentage du salaire du PDG72.4%
Durée du mandat du directeur général15.6yrs
Propriété du PDG0.3%
Durée moyenne d'occupation des postes de directionless than a year
Durée moyenne du mandat des membres du conseil d'administration7yrs

Mises à jour récentes de la gestion

Recent updates

Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Aug 17
Earnings Release: Here's Why Analysts Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Price Target To US$18.00

Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Jul 30
Molecular Templates, Inc.'s (NASDAQ:MTEM) Shares Bounce 27% But Its Business Still Trails The Industry

Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Apr 03
Little Excitement Around Molecular Templates, Inc.'s (NASDAQ:MTEM) Revenues As Shares Take 48% Pounding

Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

Dec 20
Lacklustre Performance Is Driving Molecular Templates, Inc.'s (NASDAQ:MTEM) 26% Price Drop

There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

Apr 17
There's No Escaping Molecular Templates, Inc.'s (NASDAQ:MTEM) Muted Revenues Despite A 45% Share Price Rise

What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Nov 16
What Does The Future Hold For Molecular Templates, Inc. (NASDAQ:MTEM)? These Analysts Have Been Cutting Their Estimates

Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Aug 14
Time To Worry? Analysts Are Downgrading Their Molecular Templates, Inc. (NASDAQ:MTEM) Outlook

Molecular Templates GAAP EPS of -$0.44 misses by $0.01, revenue of $4.42M misses by $2.6M

Aug 11

Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Apr 29
Rock star Growth Puts Molecular Templates (NASDAQ:MTEM) In A Position To Use Debt

Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Dec 30
Health Check: How Prudently Does Molecular Templates (NASDAQ:MTEM) Use Debt?

Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Nov 25
Some Analysts Just Cut Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

Sep 22
Is Molecular Templates (NASDAQ:MTEM) Using Debt In A Risky Way?

News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Aug 15
News Flash: Analysts Just Made A Notable Upgrade To Their Molecular Templates, Inc. (NASDAQ:MTEM) Forecasts

Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

May 18
Need To Know: Analysts Just Made A Substantial Cut To Their Molecular Templates, Inc. (NASDAQ:MTEM) Estimates

Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Mar 21
Brokers Are Upgrading Their Views On Molecular Templates, Inc. (NASDAQ:MTEM) With These New Forecasts

Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Feb 21
Need To Know: The Consensus Just Cut Its Molecular Templates, Inc. (NASDAQ:MTEM) Estimates For 2021

Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Jan 26
Is Molecular Templates (NASDAQ:MTEM) A Risky Investment?

Molecular Templates updates on study of MT5111, plans breast cancer expansion cohort in 1H21

Dec 22

Analyse de la rémunération des PDG

Comment la rémunération de Eric Poma a-t-elle évolué par rapport aux bénéfices de Molecular Templates?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$16m

Mar 31 2024n/an/a

-US$18m

Dec 31 2023US$858kUS$621k

-US$8m

Sep 30 2023n/an/a

-US$26m

Jun 30 2023n/an/a

-US$47m

Mar 31 2023n/an/a

-US$60m

Dec 31 2022US$2mUS$600k

-US$93m

Sep 30 2022n/an/a

-US$81m

Jun 30 2022n/an/a

-US$87m

Mar 31 2022n/an/a

-US$78m

Dec 31 2021US$4mUS$577k

-US$83m

Sep 30 2021n/an/a

-US$101m

Jun 30 2021n/an/a

-US$94m

Mar 31 2021n/an/a

-US$110m

Dec 31 2020US$5mUS$560k

-US$105m

Sep 30 2020n/an/a

-US$92m

Jun 30 2020n/an/a

-US$107m

Mar 31 2020n/an/a

-US$85m

Dec 31 2019US$2mUS$515k

-US$69m

Sep 30 2019n/an/a

-US$60m

Jun 30 2019n/an/a

-US$27m

Mar 31 2019n/an/a

-US$28m

Dec 31 2018US$4mUS$500k

-US$30m

Sep 30 2018n/an/a

-US$31m

Jun 30 2018n/an/a

-US$36m

Mar 31 2018n/an/a

-US$31m

Dec 31 2017US$3mUS$448k

-US$24m

Rémunération vs marché: La rémunération totale de Eric ($USD 857.77K ) est dans la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Eric a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Eric Poma (52 yo)

15.6yrs

Titularisation

US$857,769

Compensation

Dr. Eric E. Poma, Ph D., is the Chief Executive Officer and Chief Scientific Officer of Molecular Templates, Inc. since 2009 and served as its President. Dr. Poma founded Private Molecular in February 2009...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Eric Poma
CEO, Chief Scientific Officer & Director15.6yrsUS$857.77k0.28%
$ 28.9k
Jason Kim
President1.6yrsUS$579.24k0.097%
$ 9.9k
Kristen Quigley
Chief Operating Officerless than a yearpas de donnéespas de données
Grace Kim
Chief Strategy Officer & Head of IRless than a yearpas de donnéespas de données
Michelle Iwamoto-Fan
Senior Vice President & General Counselless than a yearpas de donnéespas de données
Joseph Phillips
Senior VP & Head of CMC Developmentno datapas de donnéespas de données
Chris Moore
Senior VP and Head of Preclinical Development & Translational Medicineless than a yearpas de donnéespas de données

1.0yrs

Durée moyenne de l'emploi

52yo

Âge moyen

Gestion expérimentée: L'équipe de direction de MTEM n'est pas considérée comme expérimentée (ancienneté moyenne 1 ans), ce qui suggère une nouvelle équipe.


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Eric Poma
CEO, Chief Scientific Officer & Director7yrsUS$857.77k0.28%
$ 28.9k
Michel Klein
Member of Scientific Advisory Boardno datapas de donnéespas de données
David Hoffmann
Independent Director7yrsUS$59.29k0%
$ 0
Harold Selick
Independent Chairman7yrsUS$87.29k0.041%
$ 4.2k
Kevin Lalande
Independent Director7yrsUS$54.29k0%
$ 0
Corazon Sanders
Independent Director4.7yrsUS$49.29k0%
$ 0
Burkhard Jansen
Member of Scientific Advisory Boardno datapas de donnéespas de données
Neil Berinstein
Member of Scientific Advisory Boardno datapas de donnéespas de données
Gabriela Gruia
Director2.4yrsUS$561.35k0%
$ 0

7.0yrs

Durée moyenne de l'emploi

67yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de MTEM sont considérés comme expérimentés (ancienneté moyenne 7 ans).